|Day Low/High||128.68 / 134.86|
|52 Wk Low/High||29.51 / 148.74|
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.
U.S. stocks are higher Monday thanks to a rally in crude oil.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
Tesaro's (TSRO) stock rating was lifted to 'buy' at Bank of America/Merrill Lynch.
Those who thought we were ready to break down look foolish again.
Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.